IL1B and amyloidosis: The duration of IL-1 antagonist therapy in FMF patients with amyloidosis was significantly higher than that in FMF patients without amyloidosis (69.5 months [range: 23 to 85 months] vs. 31 months [range: 5 to 84 months]; p = 0.005).